Literature DB >> 10873546

Expression of an anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin in a mutant CHO cell line.

Y Y Liu1, I Gordienko, A Mathias, S Ma, J Thompson, J H Woo, D M Neville.   

Abstract

ADP-ribosylating immunotoxins are generally expressed in Escherichia coli and then refolded in vitro. Because the efficiency of the in vitro refolding process decreases with the number of protein domains and internal disulfide bonds, these immunotoxins have been generally limited to single-chain monovalent structures. We now show that using the hamster cell line CHO K1 RE1.22c (J. M. Moehring and T. J. Moehring, 1979, Somat. Cell Genet. 5, 453-468) that has been mutated to ADP-ribosylation insensitivity, a level of 4 microg/ml of a truncated anti-T cell immunotoxin, DT390-scFvUCHT1, can be secreted into the medium. This immunotoxin is glycosylated at the two potential N-linked glycosylation sites in the toxin moiety: positions 16-18 in the A chain and residues 235-237 in the B chain. The glycosylated immunotoxin is relatively nontoxic (IC(50) 4.8 x 10(-10) M). Removal of the N-linked oligosaccharides by N-glycosidase F treatment or mutations at the two N-linked glycosylation sites results in a highly active immunotoxin with an IC(50) of 4 x 10(-12) M toward CD3(+) Jurkat cells. This is a 12-fold increase in toxicity over the same immunotoxin harvested from E. coli periplasm without refolding. A single Asn(235) Ala mutation that removed the B chain glycosylation was nearly as toxic as the double mutant. This suggests that B chain glycosylation is the major cause for the loss of toxicity. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10873546     DOI: 10.1006/prep.2000.1255

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  10 in total

1.  Overexpression of an anti-CD3 immunotoxin increases expression and secretion of molecular chaperone BiP/Kar2p by Pichia pastoris.

Authors:  Yuan Yi Liu; Jung Hee Woo; David M Neville
Journal:  Appl Environ Microbiol       Date:  2005-09       Impact factor: 4.792

2.  Development of a diphtheria toxin based antiporcine CD3 recombinant immunotoxin.

Authors:  Zhirui Wang; Raimon Duran-Struuck; Rebecca Crepeau; Abraham Matar; Isabel Hanekamp; Srimathi Srinivasan; David M Neville; David H Sachs; Christene A Huang
Journal:  Bioconjug Chem       Date:  2011-09-09       Impact factor: 4.774

3.  A truncated diphtheria toxin based recombinant porcine CTLA-4 fusion toxin.

Authors:  Jaclyn Stromp Peraino; Marian Schenk; Huiping Zhang; Guoying Li; Christina E Hermanrud; David M Neville; David H Sachs; Christene A Huang; Raimon Duran-Struuck; Zhirui Wang
Journal:  J Immunol Methods       Date:  2013-03-05       Impact factor: 2.303

4.  Increasing secretion of a bivalent anti-T-cell immunotoxin by Pichia pastoris.

Authors:  Jung Hee Woo; Yuan Yi Liu; Scott Stavrou; David M Neville
Journal:  Appl Environ Microbiol       Date:  2004-06       Impact factor: 4.792

5.  Recombinant Immunotoxin Therapy of Solid Tumors: Challenges and Strategies.

Authors:  Liang Shan; Yuanyi Liu; Paul Wang
Journal:  J Basic Clin Med       Date:  2013

6.  An anti-PSMA bivalent immunotoxin exhibits specificity and efficacy for prostate cancer imaging and therapy.

Authors:  Fayun Zhang; Liang Shan; Yuanyi Liu; David Neville; Jung-Hee Woo; Yue Chen; Alexandru Korotcov; Stephen Lin; Sophia Huang; Rajagopalan Sridhar; Wei Liang; Paul C Wang
Journal:  Adv Healthc Mater       Date:  2012-11-22       Impact factor: 9.933

Review 7.  Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges.

Authors:  Shaowei Zhu; Yuanyi Liu; Paul C Wang; Xinbin Gu; Liang Shan
Journal:  Biomed Res Int       Date:  2017-06-29       Impact factor: 3.411

Review 8.  Targeted Diphtheria Toxin-Based Therapy: A Review Article.

Authors:  Fatemeh Shafiee; Marc G Aucoin; Ali Jahanian-Najafabadi
Journal:  Front Microbiol       Date:  2019-10-18       Impact factor: 5.640

9.  A novel diphtheria toxin-based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma.

Authors:  Zeng Qi; Yue Qiu; Zhaohui Wang; Huiping Zhang; Ling Lu; Yanqiu Liu; David Mathes; Elizabeth A Pomfret; Dexiang Gao; Shi-Long Lu; Zhirui Wang
Journal:  Mol Oncol       Date:  2021-02-20       Impact factor: 6.603

Review 10.  Bacteria-derived chimeric toxins as potential anticancer agents.

Authors:  Saeed Khoshnood; Hadis Fathizadeh; Foroogh Neamati; Babak Negahdari; Piyush Baindara; Mohd Azmuddin Abdullah; Mohammad Hossein Haddadi
Journal:  Front Oncol       Date:  2022-09-07       Impact factor: 5.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.